Incyte R&D chief sells 10,801 shares under plan
INCYTE CORP (INCY) reported that officer Pablo J. Cagnoni, President, Global Head of R&D, sold 10,801 shares of common stock on 2026-08-19 in an open-market transaction at $125.56 per share, pursuant to a Rule 10b5-1 trading plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
INCYTE CORP (INCY) reported that officer Pablo J. Cagnoni, President, Global Head of R&D, sold 10,801 shares of common stock on 2026-08-19 in an open-market transaction at $125.56 per share, pursuant to a Rule 10b5-1 trading plan. Following this sale, he holds rights to 183,200 shares of common stock issuable from previously reported restricted stock units and earned performance stock units that have not yet vested.
Insights
Analyzing...
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1 | 10,801 | $125.56 | $1.36M |
Footnotes (1)
- F1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
restricted stock units financial
performance stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did INCY report for Pablo J. Cagnoni?
What is Pablo J. Cagnoni’s remaining INCY equity exposure after this Form 4 sale?
Was the INCY insider sale by Pablo J. Cagnoni under a Rule 10b5-1 plan?
What role does Pablo J. Cagnoni hold at INCYTE CORP (INCY)?
AI-generated analysis. How Rhea-AI works. Not financial advice.